ConductScience.org, home

Paper6131277

JMS, successor to cisplatin in advanced ovarian carcinoma?

Wiltshaw E and 4 others. Lancet, 1983. Cited by 53 papers, by iCite.

Cite this record

ConductScience Library. JMS, successor to cisplatin in advanced ovarian carcinoma? Papers, record 6131277. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6131277

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
JMS, successor to cisplatin in advanced ovarian carcinoma?
PubMed
Journal
Lancet
PubMed
Year
1983
PubMed
Publication types
Clinical Trial, Comparative Study, Letter, Randomized Controlled Trial
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
1.56
iCite
Revised in PubMed
2019-06-11
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wiltshaw EE
2Evans BDB D
3Jones ACA C
4Baker JWJ W
5Calvert AHA H

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Organoplatinum CompoundsMajor topic
Ovarian NeoplasmsMajor topic
Carboplatin
Cisplatin
Clinical Trials as Topic
Female
Humans
Prospective Studies
Random Allocation

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
40956032Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism.Cancer Med2025https://conductscience.org/library/papers/40956032PubMed
35477416Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.J Hematol Oncol2022https://conductscience.org/library/papers/35477416PubMed
7693428New cisplatin analogues in development. A review.Drugs1993https://conductscience.org/library/papers/7693428PubMed
6392147A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.Invest New Drugs1984https://conductscience.org/library/papers/6392147PubMed
6380788Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6380788PubMed
6371017Chemotherapy in advanced ovarian cancer.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6371017PubMed
6371015Developing new drugs for ovarian cancer: a challenging task in a changing reality.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6371015PubMed
3555590Haematological toxicity of carboplatin in rats.Br J Cancer1987https://conductscience.org/library/papers/3555590PubMed
3542270Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3542270PubMed
3539384Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3539384PubMed
3293841In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3293841PubMed
3293840Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3293840PubMed
3282706Potentiation of platinum analogue cytotoxicity by hyperthermia.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3282706PubMed
2192812Carboplatin is ototoxic.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2192812PubMed
1315566The interaction of platinum antitumour drugs with mouse liver mitochondria.Int J Exp Pathol1992https://conductscience.org/library/papers/1315566PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6131277

GET https://conductscience.org/api/papers/v1/6131277/authors